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Summary 
Background & Aims Guidelines do not recommend that 
cancer outpatients receive thromboprophylaxis unless at 
high VTE risk, with the Khorana score suggested for risk 
stratification. This study investigated VTE incidence in 
outpatients with pancreatic, endometrial, colorectal, 
ovarian and cervical cancer, the role of Khorana score in 
risk assessment, and potential risk factors. Methods 
Data was retrospectively collected 1 year after cancer 
diagnosis. VTE associated with inpatient admissions was 
excluded. Results 746 patients were included. VTE rates 
varied: 26.8% pancreatic; 5.7% endometrial; 9.8% 
colorectal; 10.2% ovarian, 0.0% cervical cancer. 
Excluding VTE at diagnosis, potentially preventable VTE 
rates were 16.5% pancreatic; 3.8% endometrial; 9.8% 
colorectal and 8.7% ovarian cancer. Khorana score was 
associated with VTE in endometrial cancer only [high-
risk:16.7% vs. low-risk:1.5%;p<0.001]. VTE rates for 
patients with central venous catheters (CVC) were 22.6-
34.8% in pancreatic, endometrial, colorectal, and ovarian 
cancers. VTE was associated with CVC in endometrial, 
colorectal, and ovarian; chemotherapy and Hb<100g/L in 
pancreatic; surgery in endometrial and ovarian, and 
BMI>35 in ovarian cancers following adjusted analysis 
(p<0.05). Conclusions VTE is a significant burden in 
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pancreatic, endometrial, colorectal and ovarian cancers. 
Khorana score was not predictive in most cancers. The 
major VTE-associated variable was CVC. Our data 
suggests a role for clinical trials of thromboprophylaxis in 
targeted cancer outpatients. 
 
Keywords 
Venous thromboembolism, Khorana score, ambulatory 
cancer, thromboprophylaxis 
 
Introduction 
 
Venous thromboembolism (VTE) causes significant 
morbidity and mortality in patients with malignancy. The 
MEGA study (2005) demonstrated that the risk of VTE 
increased seven-fold in patients with cancer, and that the 
highest risk was immediately after diagnosis, in patients 
with metastatic disease, and in those with haematological 
malignancy.1 Cancer VTE is the second leading cause of 
death in cancer patients, and it is a recognised 
independent risk factor for mortality.2 Patients with 
cancer-associated thrombosis have an increased risk of 
VTE recurrence, and of major bleeding .3,4 
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Risk assessment for VTE is now routine for both medical 
and surgical inpatients in the UK. International guidelines 
recommend thromboprophylaxis in surgical inpatients 
with a moderate VTE risk of 3%, provided bleeding risk is 
not high, and also in medical inpatients at a high risk 
(11%) of VTE.5,6 However, the role of thromboprophylaxis 
in outpatients with cancer is less clear, with guidance 
recommending that prophylaxis is not used routinely, but 
considered for those at high thrombotic risk .5,7 Some 
guidelines suggest risk stratification using the Khorana 
score (Table 1) with thromboprophylaxis considered in 
patients with a high risk score (≥3) .8,9   
 
We undertook a retrospective cohort study to investigate 
VTE incidence in the first year of diagnosis in outpatients 
diagnosed with pancreatic, endometrial, colorectal, 
ovarian or cervical cancer, at a large tertiary cancer 
centre. We reviewed the association with Khorana score 
at cancer diagnosis and investigated the role of other risk 
factors in development of cancer VTE. 
 
Methods 
 
Patient selection 
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Retrospective identification of patients with a 
multidisciplinary team (MDT) diagnosis of pancreatic, 
endometrial, colorectal, ovarian or cervical cancer, 
between 1st December 2012 – 31st December 2014, or 1st 
December 2009 – 31st December 2014 for pancreatic 
cancer patients (to ensure sufficient data). Cases were 
excluded from analysis if: VTE occurred whilst an 
inpatient or within 90 days of discharge (NHS England, 
2013); pre-existing anticoagulation at the time of VTE; 
patients who had incomplete data available to calculate a 
Khorana score; concurrent primary cancer or patients 
who did not receive all of their oncology care at the 
tertiary centre and therefore with insufficient follow-up 
data. For the main analysis, patients with VTE diagnosed 
at or before cancer diagnosis were also excluded, as the 
aim was to calculate the role of the Khorana score in 
identifying patients at risk of a VTE which could have 
potentially been prevented with thromboprophylaxis 
(Figure 1). 
 
Data collection 
For each patient, clinician reports (including clinic letters, 
chemotherapy planning documents, discharge 
summaries and MDT discussions), radiology reports, 
pathology results, electronic VTE risk assessments, 
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chemotherapy regime and electronically stored patient 
demographics were reviewed. Information on the 
following variables was collected: patient age, ethnicity, 
BMI, cancer type and stage, details of cancer therapy 
including chemotherapy, radiotherapy, and surgical 
intervention, indwelling central venous catheters as well 
as details relating to any VTE events including date, site, 
clinical presentation and treatment.  VTEs were recorded 
if documented by radiology report or clinician report of 
confirmed VTE event. Baseline/pre-chemotherapy blood 
tests were collated including haemoglobin level, 
leukocyte count, platelet count, C-reactive protein and 
creatinine level, and the Khorana score calculated. 
Cancer stage was divided into early and advanced for the 
purpose of analysis. Early stage was defined as attempt 
at curative resection in pancreatic cancer, FIGO stages 1-
3 in colorectal cancer and FIGO stages 1-2 in both 
endometrial and ovarian cancer.  
 
Statistical analysis 
Descriptive statistics were reported for patient 
demographics and treatment variables, stratified by 
cancer type to compare the different cohorts. For 
continuous variables statistics were reported in means 
(SD) or medians (IQR), where appropriate, and 
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categorical variables were reported by n (%). Clinical 
measures that are included in the Khorana score were 
grouped into high and low risk categories, corresponding 
to the thresholds when calculating the score. Similarly, 
patients were split into low risk (Khorana score <3) vs. 
high risk (Khorana score ≥3) for each cancer cohort. 
Abdominal VTE events were not included in the Khorana 
score analysis as such events were not included in the 
derivation of the score. 
 
For the inferential analyses, a binary variable was created 
for VTE development (any vs. none). Univariate 
associations were tested between VTE development and 
clinical measures that were agreed a priori as potential 
risk factors of VTE using Pearson’s chi-squared. Results 
were reported using the corresponding p-values. 
 
Stepwise logistic regression using backward elimination 
was then performed for each cancer type, using a 
significance level for removal from the model of α=0.05. 
This tested which of the VTE risk factors remained 
statistically significant after adjusting for the other factors. 
All analysis was completed using Stata version 14.0 
(StataCorp, 2015). 
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Results 
There were 878 new diagnoses of pancreatic, 
endometrial, colorectal, ovarian and cervical cancer 
between 01/12/2012 (or 01/12/2009 for pancreatic) and 
31/12/2014 (Figure 1, STROBE diagram). 113 patients 
were excluded from the study due to pre-existing 
anticoagulation or incomplete data. 19 further patients 
were excluded as the thrombotic event occurred during 
patient admission or within 90 days of discharge or 
surgery (hospital acquired thrombosis, HAT). 746 patients 
were therefore included in the study: 97 pancreatic 
cancer diagnoses, 157 endometrial cancer, 205 
colorectal cancer, 196 ovarian cancer, and 91 cervical 
cases. Patients who presented with a VTE at time of 
cancer diagnosis (n=16) were excluded from the 
subsequent VTE risk factor analysis. Patient and 
treatment characteristics of patients included in the VTE 
risk factor analysis are shown in Table 2. 
  
VTE incidence  
Rates of total VTEs and potentially preventable VTEs 
(Figure 2) were recorded for each cancer group. 
 
VTE demographics 
 9 
Pancreatic cancer 26 patients with VTE diagnosed 
during the first year of cancer diagnosis developed 31 
individual clots (9 lower limb deep vein thrombosis (LL-
DVT), 3 upper limb DVT (UL-DVT) [all central venous 
catheter (CVC) associated], 5 pulmonary emboli (PE), 1 
inferior vena cava (IVC), and 13 intra-abdominal 
thromboses comprising of portal, splenic, hepatic, 
superior mesenteric and renal vein thromboses). Of these 
patients, 13/26 had symptomatic VTE, whilst the 
remaining patients had VTE incidentally found on staging 
scans – the majority of these were intra-abdominal VTE 
(5 portal vein, 4 splenic vein, 1 hepatic vein, 1 renal vein, 
1 superior mesenteric vein) as well as 2 incidental PEs. 
14/26 patients were treated with low molecular weight 
heparin (LWMH). Untreated patients were asymptomatic 
or had contraindication to anticoagulation.  
 
Endometrial cancer 9 patients with VTE diagnosed 
during the first year of diagnosis developed 10 individual 
clots (2 LL-DVT, 1 UL-DVT [CVC associated], 7 PE). 6/9 
were symptomatic, with 3 incidental PEs found on staging 
CT scans. All received treatment dose LMWH.  
 
Colorectal cancer 20 patients with VTE diagnosed within 
the first year developed 21 individual VTE episodes (5 
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LL-DVT, 5 UL-DVT [all CVC associated], 8 PE, 1 neck, 2 
portal vein thromboses). 9/20 patients were 
asymptomatic (7 incidentally found PE and 2 incidentally 
found portal vein thromboses on staging scans). The 
majority of patients (18/20) were treated with LMWH. Of 
the remaining 2 patients, 1 died prior to treatment 
commencing, and the other had a small non-occlusive 
CVC-associated DVT which was managed by removal of 
the line only. 
 
Ovarian cancer 20 patients with VTE diagnosed within 
the first year developed 23 individual clots (5 lower limb 
DVT, 4 upper limb DVT [all PICC-associated], 12 
pulmonary emboli, 2 inferior vena cava thromboses). 
14/21 patients had symptomatic VTE, 7 asymptomatic, 1 
patient had 3 individual events (1 symptomatic PE, 
followed by separate lower limb and IVC thromboses 
incidentally found on staging scans). 20/21 patients 
received LMWH. In the remaining patient anticoagulation 
was contraindicated due to high bleeding risk outweighing 
benefit for treating small incidental PEs.  
 
Cervical cancer None of the 91 patients diagnosed with 
cervical cancer had a VTE unrelated to an inpatient stay 
or surgery in the first year following diagnosis.  
 11 
 
Association with Khorana score 
Patients were divided into high risk (≥3) and low risk (<3) 
groups by Khorana score at diagnosis (excluding those 
with abdominal VTE). In all groups except for endometrial 
cancer, a high risk Khorana score was not associated 
with a higher VTE rate (Figures 3A-D). 
  
Association with other variables 
The association between the development of VTE in the 
first year of cancer diagnosis with background and 
treatment variables were analysed (Table 3). In all cancer 
groups (excluding cervical cancer where no patient 
developed a VTE), VTE development was univariately 
associated with indwelling central venous catheters 
(CVC) (p<0.05). In endometrial and colorectal cancers 
chemotherapy use was significantly associated with VTE 
development; and in pancreatic, endometrial and ovarian 
cancers surgical intervention was significantly associated, 
even after exclusion of VTE occurring within 90 days of 
surgery. BMI was only associated with VTE development 
in ovarian cancer; and full blood count parameters used 
in the calculation of the Khorana score (platelet count 
350 x 109, Hb level <100g/l, leukocyte count >11 x 109) 
were only associated with VTE development in 
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endometrial cancer. Finally, advanced stage of cancer 
was univariately associated with VTE development in 
endometrial and ovarian cancer.  
 
Risk factors that remained statistically significant after 
stepwise logistic regression were indwelling CVC for 
endometrial, colorectal and ovarian cancers; 
chemotherapy for pancreatic cancer only; surgery for 
endometrial and ovarian cancers; Hb <100g/L for 
pancreatic cancer; BMI>35 for ovarian cancer; and 
surgical intervention for endometrial and ovarian cancers.  
 
The VTE rate for patients with indwelling lines were: 
34.8% (8/23) for pancreatic; 25.0% (2/8) for endometrial; 
22.6% (14/62) for colorectal and 22.7% (5/22) for ovarian. 
The VTE rate for patients having chemotherapy were: 
23.2% (13/56) for pancreatic; 9.1% (4/44) for endometrial; 
16.4% (19/116) for colorectal and 10.1% (15/148) for 
ovarian. Numbers were too small for further subgroup 
partitioning within subgroups. 
  
The number of days between cancer and potentially 
preventable VTE diagnosis was calculated. The median 
(IQR) time to VTE was 24 days in endometrial cancer (7-
62 days); 61 days (14-153) in ovarian cancer; 90 days 
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(42-191) in pancreatic cancer and 122 days (64-153) in 
colorectal cancer. 
 
Discussion 
This retrospective cohort study of ambulatory cancer 
patients demonstrates a significant burden of VTE in the 
first year of diagnosis in four out of five cancer groups 
analysed. The exception to this is cervical cancer in 
which there were no VTE unrelated to an inpatient stay or 
surgery. However, 4/91 cervical cancer patients 
developed VTE which were all associated with short day-
case surgical procedures (3 EUA and 1 laparoscopic 
EUA) defined as “low risk” on local VTE risk assessment 
and thus did not receive post-operative 
thromboprophylaxis  
 
The total rates of VTE were 26.8%, 5.7%, 9.8%, 10.2% 
and 0.0% for pancreatic, endometrial, colorectal, ovarian 
and cervical cancers respectively. Even excluding those 
patients who presented with VTE or had thrombosis 
diagnosed on initial staging scans, the majority of patients 
with these cancers had a VTE that was potentially 
preventable with thromboprophylaxis. However, this is not 
routine clinical practice for outpatients, despite being a 
quality standard in hospitalised patients.10 International 
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ACCP guidelines currently recommend that clinicians 
should not routinely offer pharmacological VTE 
prophylaxis to outpatients with cancer, but recommend 
prophylactic LMWH for patients with low bleeding risk and 
additional risk factors including previous VTE, 
immobilisation, hormonal therapies, angiogenesis 
inhibitors, thalidomide and lenalidomide.5 More recent 
guidelines suggest the use of the Khorana score for risk 
stratification.8 
 
However, our data suggests that the Khorana score is not 
valuable in risk stratifying patients with pancreatic, 
colorectal, and ovarian cancers, although a higher 
Khorana score was predictive of 1-year VTE development 
in endometrial cancer. Furthermore, use of the Khorana 
score to define who may benefit from prophylactic 
anticoagulation in the cervical cancer cohort would have 
potentially meant all 25 patients with a high-risk score 
were unnecessarily anticoagulated, since none 
developed a VTE which was not associated with an 
inpatient admission or surgery.  
 
We investigated other variables associated with VTE 
development in ambulatory cancer patients. Risk factors 
which remained statistically significant after stepwise 
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logistic regression were indwelling CVC for endometrial, 
colorectal, and ovarian cancers; chemotherapy for 
pancreatic cancer only; surgery for endometrial and 
ovarian cancers; Hb<100g/L for pancreatic cancer and 
BMI>35 for ovarian cancer. The VTE rate for patients with 
indwelling lines were particularly high, with around a 
quarter of endometrial, colorectal and ovarian; and over a 
third of pancreatic cancer patients with CVC developing 
VTE, either local or systemic. 
 
Improving risk stratification in ambulatory cancer patients 
is likely to have an impact on morbidity due to the high 
burden of VTE incidence demonstrated in this study. The 
VTE risk in patients with malignancy is greatest in the first 
year following diagnosis, so it is important to develop 
simple and reliable methods to risk stratify in the MDT or 
outpatient department soon after diagnosis.11 Despite 
some studies suggesting that bleeding rates with use of 
anticoagulants in cancer patients are higher than in 
patients without malignancy, large studies have refuted 
this and there is no evidence suggesting this is the case 
with primary thromboprophylaxis.7,12  
 
An obvious limitation is that this is a retrospective study. 
However, it includes a large cohort and provides 
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important information to guide future prospective 
investigations of thromboprophylaxis in ambulatory 
cancer patients, in particular, factors to identify those at 
high risk. Oncology care was delivered at our tertiary 
centre but some patients may have consulted their local 
hospitals with acute presentations, including of VTE. 
Thus, our data may in fact underestimate the incidence of 
VTEs and this may explain in part why there were no VTE 
diagnoses in the cervical cancer cohort. Future 
multicentre prospective studies looking at additional 
tumour groups would be of value in further evaluating the 
extent of the clinical problem.  
 
In summary, this retrospective cohort study at a tertiary 
oncology centre has identified a significant burden of VTE 
in pancreatic, endometrial, colorectal, and ovarian cancer 
cohorts. Khorana score did not predict risk of VTE 
development in pancreatic, colorectal, ovarian or cervical 
cancer groups, although it was predictive in patients with 
endometrial cancer. The major variable associated with 
VTE development was indwelling CVC with VTE rates of 
23-35% depending on tumour type. Our data suggests a 
role for clinical trials of routine thromboprophylaxis in 
targeted groups of cancer outpatients, such as those with 
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pancreatic cancer, or with endometrial, colorectal and 
ovarian cancers and indwelling central venous catheters. 
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